484 related articles for article (PubMed ID: 24501009)
1. A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.
Reckamp KL; Giaccone G; Camidge DR; Gadgeel SM; Khuri FR; Engelman JA; Koczywas M; Rajan A; Campbell AK; Gernhardt D; Ruiz-Garcia A; Letrent S; Liang J; Taylor I; O'Connell JP; Jänne PA
Cancer; 2014 Apr; 120(8):1145-54. PubMed ID: 24501009
[TBL] [Abstract][Full Text] [Related]
2. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.
Ramalingam SS; Blackhall F; Krzakowski M; Barrios CH; Park K; Bover I; Seog Heo D; Rosell R; Talbot DC; Frank R; Letrent SP; Ruiz-Garcia A; Taylor I; Liang JQ; Campbell AK; O'Connell J; Boyer M
J Clin Oncol; 2012 Sep; 30(27):3337-44. PubMed ID: 22753918
[TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of dacomitinib in korean patients with KRAS wild-type advanced non-small-cell lung cancer refractory to chemotherapy and erlotinib or gefitinib: a phase I/II trial.
Park K; Cho BC; Kim DW; Ahn MJ; Lee SY; Gernhardt D; Taylor I; Campbell AK; Zhang H; Giri N; Letrent SP; O'Connell J; Heo DS
J Thorac Oncol; 2014 Oct; 9(10):1523-31. PubMed ID: 25521398
[TBL] [Abstract][Full Text] [Related]
4. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial.
Ramalingam SS; Jänne PA; Mok T; O'Byrne K; Boyer MJ; Von Pawel J; Pluzanski A; Shtivelband M; Docampo LI; Bennouna J; Zhang H; Liang JQ; Doherty JP; Taylor I; Mather CB; Goldberg Z; O'Connell J; Paz-Ares L
Lancet Oncol; 2014 Nov; 15(12):1369-78. PubMed ID: 25439691
[TBL] [Abstract][Full Text] [Related]
5. Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials.
Ramalingam SS; O'Byrne K; Boyer M; Mok T; Jänne PA; Zhang H; Liang J; Taylor I; Sbar EI; Paz-Ares L
Ann Oncol; 2016 Mar; 27(3):423-9. PubMed ID: 26768165
[TBL] [Abstract][Full Text] [Related]
6. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial.
Wu YL; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Tsuji F; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Nadanaciva S; Sandin R; Mok TS
Lancet Oncol; 2017 Nov; 18(11):1454-1466. PubMed ID: 28958502
[TBL] [Abstract][Full Text] [Related]
7. Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial.
Jänne PA; Ou SI; Kim DW; Oxnard GR; Martins R; Kris MG; Dunphy F; Nishio M; O'Connell J; Paweletz C; Taylor I; Zhang H; Goldberg Z; Mok T
Lancet Oncol; 2014 Dec; 15(13):1433-1441. PubMed ID: 25456362
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial of erlotinib monotherapy for pretreated elderly patients with advanced EGFR wild-type non-small cell lung cancer.
Minemura H; Yokouchi H; Azuma K; Hirai K; Sekine S; Oshima K; Kanazawa K; Tanino Y; Inokoshi Y; Ishii T; Katsuura Y; Oishi A; Ishida T; Munakata M
BMC Res Notes; 2015 Jun; 8():220. PubMed ID: 26043909
[TBL] [Abstract][Full Text] [Related]
9. Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Ellis PM; Shepherd FA; Millward M; Perrone F; Seymour L; Liu G; Sun S; Cho BC; Morabito A; Leighl NB; Stockler MR; Lee CW; Wierzbicki R; Cohen V; Blais N; Sangha RS; Favaretto AG; Kang JH; Tsao MS; Wilson CF; Goldberg Z; Ding K; Goss GD; Bradbury PA; ; ;
Lancet Oncol; 2014 Nov; 15(12):1379-88. PubMed ID: 25439692
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
Nishio M; Kato T; Niho S; Yamamoto N; Takahashi T; Nogami N; Kaneda H; Fujita Y; Wilner K; Yoshida M; Isozaki M; Wada S; Tsuji F; Nakagawa K
Cancer Sci; 2020 May; 111(5):1724-1738. PubMed ID: 32159882
[TBL] [Abstract][Full Text] [Related]
11. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
Kris MG; Camidge DR; Giaccone G; Hida T; Li BT; O'Connell J; Taylor I; Zhang H; Arcila ME; Goldberg Z; Jänne PA
Ann Oncol; 2015 Jul; 26(7):1421-7. PubMed ID: 25899785
[TBL] [Abstract][Full Text] [Related]
12. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
[TBL] [Abstract][Full Text] [Related]
13. Dacomitinib in the Management of Advanced Non-Small-Cell Lung Cancer.
Lau SCM; Batra U; Mok TSK; Loong HH
Drugs; 2019 Jun; 79(8):823-831. PubMed ID: 31069718
[TBL] [Abstract][Full Text] [Related]
14. Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives.
Lavacchi D; Mazzoni F; Giaccone G
Drug Des Devel Ther; 2019; 13():3187-3198. PubMed ID: 31564835
[TBL] [Abstract][Full Text] [Related]
15. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K; Garon EB; Seto T; Nishio M; Ponce Aix S; Paz-Ares L; Chiu CH; Park K; Novello S; Nadal E; Imamura F; Yoh K; Shih JY; Au KH; Moro-Sibilot D; Enatsu S; Zimmermann A; Frimodt-Moller B; Visseren-Grul C; Reck M;
Lancet Oncol; 2019 Dec; 20(12):1655-1669. PubMed ID: 31591063
[TBL] [Abstract][Full Text] [Related]
16. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C
Lancet Oncol; 2011 Aug; 12(8):735-42. PubMed ID: 21783417
[TBL] [Abstract][Full Text] [Related]
17. First-line therapy with dacomitinib, an orally available pan-HER tyrosine kinase inhibitor, for locally advanced or metastatic penile squamous cell carcinoma: results of an open-label, single-arm, single-centre, phase 2 study.
Necchi A; Lo Vullo S; Perrone F; Raggi D; Giannatempo P; Calareso G; Nicolai N; Piva L; Biasoni D; Catanzaro M; Torelli T; Stagni S; Togliardi E; Colecchia M; Busico A; Gloghini A; Testi A; Mariani L; Salvioni R
BJU Int; 2018 Mar; 121(3):348-356. PubMed ID: 28921872
[TBL] [Abstract][Full Text] [Related]
18. Dacomitinib, a second-generation irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) to treat non-small cell lung cancer.
Nagano T; Tachihara M; Nishimura Y
Drugs Today (Barc); 2019 Apr; 55(4):231-236. PubMed ID: 31050691
[TBL] [Abstract][Full Text] [Related]
19. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations.
Mok TS; Cheng Y; Zhou X; Lee KH; Nakagawa K; Niho S; Lee M; Linke R; Rosell R; Corral J; Migliorino MR; Pluzanski A; Sbar EI; Wang T; White JL; Wu YL
J Clin Oncol; 2018 Aug; 36(22):2244-2250. PubMed ID: 29864379
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib, cabozantinib, or erlotinib plus cabozantinib as second-line or third-line treatment of patients with EGFR wild-type advanced non-small-cell lung cancer (ECOG-ACRIN 1512): a randomised, controlled, open-label, multicentre, phase 2 trial.
Neal JW; Dahlberg SE; Wakelee HA; Aisner SC; Bowden M; Huang Y; Carbone DP; Gerstner GJ; Lerner RE; Rubin JL; Owonikoko TK; Stella PJ; Steen PD; Khalid AA; Ramalingam SS;
Lancet Oncol; 2016 Dec; 17(12):1661-1671. PubMed ID: 27825638
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
